Susquehanna International Group
AGRX

Susquehanna International Group’s Agile Therapeutics AGRX Stock Holding History

Susquehanna International Group’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5
Closed -$22K – 13509
2021
Q1 		$22K Hold
5
– – ﹤0.01% 12135
2020
Q4 		$29K Sell
5
-25
-83% -$147K ﹤0.01% 10849
2020
Q3 		$183K Sell
30
-28
-48% -$160K ﹤0.01% 9528
2020
Q2 		$322K Buy
58
+31
+115% +$161K ﹤0.01% 8234
2020
Q1 		$101K Sell
27
-22
-45% -$126K ﹤0.01% 9318
2019
Q4 		$246K Buy
+49
New +$171K ﹤0.01% 8394

Other funds holding AGRX

LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Susquehanna International Group's AGRX Position: Q1 2023 in Review

Susquehanna International Group sold out of Agile Therapeutics (AGRX) in Q1 2023, closing a stake of 289 shares — an estimated $3.28K sold.

Susquehanna International Group first reported a position in AGRX in Q4 2016 and held it in 18 quarters. The position peaked at $1.23M in Q1 2020. 22 funds tracked by Wall St. Rank hold AGRX as of Q1 2023.

  • Susquehanna International Group reported no remaining Agile Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Susquehanna International Group sold 289 Agile Therapeutics shares in Q1 2023, an estimated $3.28K.
  • Susquehanna International Group first reported a position in Agile Therapeutics in Q4 2016 and held it in 18 quarters.
  • Susquehanna International Group's Agile Therapeutics position peaked at $1.23M in Q1 2020.
  • 22 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2023.

Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.